(Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | (FY)Dec 31, 2021 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 11.99%965.06M | -7.40%4.2B | -12.66%2.95B | -15.10%1.78B | -18.01%861.72M | 0.90%4.53B | 7.78%3.38B | 6.02%2.1B | 5.01%1.05B | 4.07%4.49B |
Operating income | -7.40%4.2B | -15.10%1.78B | 0.90%4.53B | 6.02%2.1B | 4.07%4.49B | |||||
Cost of sales | ---- | 9.95%-3.39B | ---- | 14.26%-1.5B | ---- | 1.43%-3.76B | ---- | -2.11%-1.75B | ---- | -2.20%-3.82B |
Operating expenses | 9.95%-3.39B | 14.26%-1.5B | 1.43%-3.76B | -2.11%-1.75B | -2.20%-3.82B | |||||
Gross profit | 5.12%807.14M | -19.29%283.15M | 14.09%767.84M | 31.02%350.84M | 16.08%673.01M | |||||
Selling expenses | ---- | -12.83%-104.61M | ---- | -1.56%-46.6M | ---- | 11.42%-92.72M | ---- | 9.37%-45.88M | ---- | -8.31%-104.67M |
Administrative expenses | ---- | -46.82%-190.85M | ---- | 12.39%-70.78M | ---- | 19.38%-129.99M | ---- | 10.86%-80.78M | ---- | -20.46%-161.24M |
Research and development expenses | ---- | -4.04%-307.66M | ---- | -2.55%-139.26M | ---- | 1.71%-295.71M | ---- | -3.49%-135.81M | ---- | -27.94%-300.85M |
Impairment and provision | ---- | -1,044.30%-2.24M | ---- | -318.68%-1.14M | ---- | 61.22%237K | ---- | -160.67%-273K | ---- | 166.82%147K |
-Other impairment is provision | ---- | -1,044.30%-2.24M | ---- | -318.68%-1.14M | ---- | 61.22%237K | ---- | -160.67%-273K | ---- | 166.82%147K |
Special items of operating profit | ---- | 5.78%61.06M | ---- | -31.55%21.79M | ---- | -17.85%57.72M | ---- | 57.75%31.84M | ---- | 548.22%70.26M |
Operating profit | -14.49%262.83M | -60.67%47.17M | 73.99%307.38M | 652.94%119.94M | 41.61%176.67M | |||||
Financing income | ---- | 78.23%30.12M | ---- | 125.73%14.91M | ---- | 53.94%16.9M | ---- | 12.14%6.6M | ---- | -37.66%10.98M |
Financing cost | ---- | -107.28%-63.37M | ---- | -207.84%-26.78M | ---- | -140.35%-30.57M | ---- | -34.94%-8.7M | ---- | 25.15%-12.72M |
Share of profits of associates | ---- | 15.27%-21.74M | ---- | -16.76%-11.98M | ---- | -237.57%-25.66M | ---- | -584.07%-10.26M | ---- | 14.13%-7.6M |
Special items of earning before tax | ---- | -41.20%-28.39M | ---- | ---15.8M | ---- | ---20.11M | ---- | ---- | ---- | ---- |
Earning before tax | -27.62%179.46M | -93.01%7.53M | 48.18%247.95M | 675.53%107.58M | 43.60%167.33M | |||||
Tax | ---- | 35.73%-49.88M | ---- | 26.66%-16.2M | ---- | -154.09%-77.61M | ---- | -268.74%-22.1M | ---- | 58.70%-30.54M |
After-tax profit from continuing operations | 209.72%10.2M | -23.93%129.57M | -65.81%46.23M | -110.15%-8.68M | -130.39%-9.3M | 24.53%170.34M | 199.76%135.21M | 984.85%85.49M | 169.37%30.59M | 221.28%136.78M |
Earning after tax | -23.93%129.57M | -110.15%-8.68M | 24.53%170.34M | 984.85%85.49M | 221.28%136.78M | |||||
Minority profit | ---- | -16.32%605K | ---- | -26.02%273K | ---- | 185.87%723K | ---- | 126.66%369K | ---- | -1,375.76%-842K |
Profit attributable to shareholders | -23.97%128.97M | -110.52%-8.95M | 23.25%169.62M | 818.79%85.12M | 223.75%137.63M | |||||
Basic earnings per share | -24.79%0.0182 | -110.57%-0.0013 | 18.63%0.0242 | 778.57%0.0123 | 218.75%0.0204 | |||||
Diluted earnings per share | -24.17%0.0182 | -110.66%-0.0013 | 20.60%0.024 | 838.46%0.0122 | 220.97%0.0199 | |||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion |
Auditor | -- | PricewaterhouseCoopers | -- | -- | -- | PricewaterhouseCoopers | -- | -- | -- | PricewaterhouseCoopers |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data